Yarrow Bioscience (YARW) Cash from Financing Activities (2017 - 2026)
Yarrow Bioscience's (YARW) quarterly Cash from Financing Activities came in at -$15000.0 in Q1 2026, up 82.76% YoY from -$8207.5 in Q1 2025, and up 55.88% on a QoQ basis from -$34000.0 in Q2 2025.
Yarrow Bioscience (YARW) Cash from Financing Activities (2017 - 2026) Analysis & Trends
Yarrow Bioscience (YARW) has 10 years of Cash from Financing Activities data on file, last reported at -$15000.0 in Q1 2026.
- Quarterly Cash from Financing Activities rose 82.76% year-over-year to -$15000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$268000.0 (down 20.18% YoY) and the FY2025 annual result came in at -$143000.0, down 1.42% from the prior year.
- Cash from Financing Activities grew to -$15000.0 in Q1 2026, from -$34000.0 in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $82.7 million in Q4 2023 to a low of -$217000.0 in Q1 2023.
- A 5-year average of $5.6 million and a median of -$15000.0 in 2026 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2023 — Cash from Financing Activities jumped 39641.83% — and 2025, when it sank 1640.0%.
- Tracing YARW's Cash from Financing Activities over 5 years: stood at $208000.0 in 2022, then jumped by 39641.83% to $82.7 million in 2023, then slumped by 100.16% to -$132000.0 in 2024, then jumped by 74.24% to -$34000.0 in 2025, then surged by 55.88% to -$15000.0 in 2026.
- The last three Cash from Financing Activities figures came in at -$15000.0 (Q1 2026), -$34000.0 (Q2 2025), and -$87000.0 (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Yarrow Bioscience | 31.25 Mn | 8.33 Mn | - | -14,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -14,000.00 |
| Jun 30, 2026 | -14,000.00 |
| Mar 31, 2026 | -15,000.00 |
| Mar 31, 2026 | -15,000.00 |
| Jun 30, 2025 | -34,000.00 |
| Jun 30, 2025 | -34,000.00 |
| Mar 31, 2025 | -87,000.00 |
| Mar 31, 2025 | -87,000.00 |
| Dec 31, 2024 | -132,000.00 |
| Dec 31, 2024 | -132,000.00 |
| Sep 30, 2024 | -2,000.00 |
| Sep 30, 2024 | -2,000.00 |
| Jun 30, 2024 | -2,000.00 |
| Jun 30, 2024 | -2,000.00 |
| Mar 31, 2024 | -5,000.00 |
| Mar 31, 2024 | -5,000.00 |
| Dec 31, 2023 | 82.66 Mn |
| Dec 31, 2023 | 82.66 Mn |
| Sep 30, 2023 | -47,000.00 |
| Sep 30, 2023 | -47,000.00 |